Services to the Homeless with Serious Mental Illness: From an Occ
Journal of Clinical Trials

Journal of Clinical Trials
Open Access

ISSN: 2167-0870

+44 7868 792050

Editorial - (2012) Volume 2, Issue 4

Services to the Homeless with Serious Mental Illness: From an Occupational Therapy Perspective

Emily F Piven*
Health Matters First of Florida Inc., USA
*Corresponding Author: Emily F Piven, OTD, MHE, OTR, Health Matters First of Florida Inc., P.O. Box 64, Oakland Florida, 34760, USA, Fax: (407) 656-0974 Email:

Keywords: Homelessness, Mental health, Occupational therapy

Sugammadex, a γ-cyclodextrin that encapsulates selectively steroidal neuromuscular blocking agents, such as rocuronium or vecuronium, has changed the face of clinical neuromuscular pharmacology. Sugammadex allows a rapid reversal of muscle paralysis. After its injection, a train-of-four ratio >0.9 is obtained in less than 5 minutes in all patients, whatever the degree of muscle paralysis and even when anesthesia is maintained with halogenated agents. Sugammadex in blood-brain barrier penetration is poor (<3% in rats). However the blood brain barrier permeability can be altered under different conditions (i.e. neurodegenerative diseases, trauma, ischemia, infections, or immature nervous system). We show here that clinically relevant sugammadex concentrations cause apoptotic neuron death in primary cultures.

A Cochrane systematic review including 18 randomized controlled trials (with a total of 1321 patients) on the efficacy and Safety of Sugammadex (SUG) concluded that it was more effective than placebo (no medication) or neostigmine in reversing muscle relaxation caused by Neuromuscular Blockade (NMB) during surgery and is relatively safe. Serious complications occurred in less than 1% of the patients who received SUG [1]. Reported side effects for SUG included cough, dry mouth, temperature changes, parasomia, paresthesia, movement during surgery, mild erythemia, abdominal discomfort, tachycardia, bradycardia, dizziness, increased creatinine phosphokinase, and increased B2 microglobinuria [2]. Pooled preclinical safety data obtained from the US FDA briefing document [3]; and the European Medicines Agency scientific document [4] reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to reproduction, local tolerance or compatibility with blood. Potential kidney and lung toxicity of cyclodextrins, if large repeated doses are administered, must be also taken into account [5]. Besides, available information regarding SUG on special conditions/population, including renal impairment, elderly patients, obese patients, and pediatric population is really limited [3,4,6].

SUG exhibits a very low transfer across the Blood-Brain Barrier (BBB) and the placenta. Nevertheless, different clinical conditions imply moderate or severe alterations of the BBB integrity, i.e. Alzheimer [7], Parkinson [8] or multiple sclerosis [9] disease-associated neurodegeneration, traumatic brain/spinal cord injury [10], ischemia [11], meningitis [12], or immature nervous system [13]. Under these clinical conditions, SUG may cross the BBB in specific areas. SUG can act such as potential induced neuronal toxicity.

SUG causes cell death, predominantly by apoptosis, in cultured neurons [14,15]. Apoptosis induction associates with an alteration in neuronal cholesterol homeostasis [15]. In fact, neuronal death caused by inhibition of intracellular cholesterol trafficking has been shown to be caspase dependent and associated with activation of the mitochondrial apoptosis pathway [16]. Cholesterol is an abundant component of plasma membranes of eukaryotic cells and is an essential regulator of membrane fluidity, permeability, receptor function, and ion channel activity [17].

Nevertheless cholesterol accumulation may be a double edge sword since, as other reports suggest, excessive accumulation of cholesterol in mitochondria may be a key step in promoting e.g. Alzheimer disease progression [18]. In this scenario U18666A, a cholesterol transportinhibiting agent, leads to high intracellular cholesterol accumulation in primary cortical neurons, activation of caspases and calpains, hyperphosphorylation of tau, and apoptosis [19].

The potential association of SUG-induced alteration in cholesterol homeostasis with oxidative stress and apoptosis activation, the fact that resistance/sensitivity to oxidative stress may likely differ between brain regions and neuronal cell types, potential neurons-astrocytes interactions, as well as modulation by pathological mechanisms such as inflammation, all represent new research windows that deserve further studies.


  1. Abrishami A, Ho J, Wong J, Yin L, Chung F (2009) Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database Syst Rev: CD007362.
  2. Kovac AL (2009) Sugammadex: the first selective binding reversal agent for neuromuscular block. J Clin Anesth 21: 444-453.
  3. FDA (2008) Food and Drug Administration. Anesthetic and Life Support Advisory Committee Meeting sugammadex sodium injection.
  4. EMEA (2008) European Medicines Agency: European Public Assessment Report for Bridion sugammadex.
  5. Laza-Knoerr AL, Gref R, Couvreur P (2010) Cyclodextrins for drug delivery. J Drug Target 18: 645-656.
  6. Akha AS, Rosa J 3rd, Jahr JS, Li A, Kiai K (2010) Sugammadex: cyclodextrins, development of selective binding agents, pharmacology, clinical development, and future directions. Anesthesiol Clin 28: 691-708.
  7. Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118: 103-113.
  8. Stolp HB, Dziegielewska KM (2009) Review: Role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Neuropathol Appl Neurobiol 35: 132-146.
  9. Waubant E (2006) Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis. Dis Markers 22: 235-244.
  10. Shlosberg D, Benifla M, Kaufer D, Friedman A (2010) Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol 6: 393-403.
  11. Kaur C, Ling EA (2008) Blood brain barrier in hypoxic-ischemic conditions. Curr Neurovasc Res 5: 71-81.
  12. Mook-Kanamori BB, Geldhoff M, van der Poll T, van de Beek D (2011) Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev 24: 557-591.
  13. Saunders NR, Knott GW, Dziegielewska KM (2000) Barriers in the immature brain. Cell Mol Neurobiol 20: 29-40.
  14. Valles SL, Borras C, Gambini J, Furriol J, Ortega A, et al. (2008) Oestradiol or genistein rescues neurons from amyloid beta-induced cell death by inhibiting activation of p38. Aging Cell 7: 112-118.
  15. Huang Z, Hou Q, Cheung NS, Li QT (2006) Neuronal cell death caused by inhibition of intracellular cholesterol trafficking is caspase dependent and associated with activation of the mitochondrial apoptosis pathway. J Neurochem 97: 280-291.
  16. Brown DA, London E (1998) Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 14: 111
  17. Garcia-Ruiz C, Mari M, Colell A, Morales A, Caballero F, et al. (2009) Mitochondrial cholesterol in health and disease. Histol Histopathol 24: 117-132.
  18. Koh CH, Qi RZ, Qu D, Melendez A, Manikandan J, et al. (2006) U18666A-mediated apoptosis in cultured murine cortical neurons: role of caspases, calpains and kinases. Cell Signal 18: 1572-1583.
Citation: Valles SL (2012) Suggamadex Produce Neuron Cell Death in Primary Culture. J Clin Trials 1:e112.

Copyright: © 2012 Valles SL. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.